Home > Healthcare > Pharmaceuticals > Finished Drug Form > Hypopigmentation Disorder Treatment Market

Hypopigmentation Disorder Treatment Market – By Treatment Type (Drugs {Corticosteroids, Melanocyte-Stimulating Hormone}, Procedures {Laser treatment, Phototherapy}), Disease Indication (Vitiligo, Albinism), Global Forecast 2024 – 2032

  • Report ID: GMI8575
  • Published Date: Mar 2024
  • Report Format: PDF

Hypopigmentation Disorder Treatment Market Size

Hypopigmentation Disorder Treatment Market size was valued at USD 3.1 billion in 2023 and is expected to grow at a CAGR of 6.1% between 2024 and 2032. The increasing prevalence of pigmentation disorders such as vitiligo and albinism, along with rising awareness among the population, is impelling the market growth.

For instance, according to a research study published by National Library of Medicine in 2021, vitiligo prevalence among adults in the U.S. is estimated to be around 1.38%, with 0.77% being diagnosed and 0.61% undiagnosed. This skin condition affects individuals regardless of age, with a significant impact on patients and often associated with other autoimmune comorbid conditions. Thus, the high prevalence of hypopigmentation disorders is anticipated to generate opportunities for market expansion globally.

Hypopigmentation disorders refer to conditions where there is a loss or reduction of pigment in the skin, resulting in lighter patches compared to the surrounding skin. These disorders are caused by various factors, including genetic predisposition, autoimmune reactions, environmental factors, or trauma. Few of the common hypopigmentation disorders include vitiligo, albinism, and post-inflammatory hypopigmentation.

Hypopigmentation Disorder Treatment Market Trends

  • The growing involvement of the companies in the research and development activities for the development of drugs along with growing clinical trials in the field of dermatology is projected to propel the market over the forecast period. For instance, as per the National Clinical Trials Registry, 41 active trials related to vitiligo were ongoing in the U.S. as of November 23, 2022.
  • Similarly, in August 2021, clinical trial for the treatment of vitiligo was carried out in Mexico medical facility. Thus, growing clinical trials especially for vitiligo will further support the market expansion.

Hypopigmentation Disorder Treatment Market Analysis

Hypopigmentation Disorder Treatment Market, By Treatment Type, 2021 – 2032 (USD Billion)

Based on the treatment type, the market is classified into drugs and procedures. The drugs segment dominated the market with revenue of USD 1.8 billion in 2023.

  • The segmental growth is attributable to the expanded research and development activities and product launches by major market players in the industry. Also, the increasing usage of topical administration for vitiligo treatment is expected to increase the demand for drugs, thereby boosting the segment growth.
  • Further, administration of corticosteroids including betamethasone valerate, fluticasone propionate, and hydrocortisone butyrate is highly recommended for treating several pigmentation disorders. Thus, availability of wide range of drugs in the market is expected to spur the segment expansion.


Hypopigmentation Disorder Treatment Market, By Disease Indication (2023)

Based on disease indication, the hypopigmentation disorder treatment market is classified into vitiligo, albinism, and other disease indications. The albinism segment is expected to exhibit CAGR of 5.9% between 2024 – 2032 period.

  • The high segment growth is primarily due to the increasing prevalence of albinism. For instance, as per an article published in August 2022 by StatPearls, it was disclosed that the American region exhibited the significant occurrence of oculocutaneous albinism type 2, with a prevalence rate of 1 in 36,000. Thus, with the increasing prevalence of albinism, the surge in demand for treatments targeting pigmentation disorders treatment is expected to spur the segment landscape.
  • Additionally, pharmaceutical companies and research institutions are actively engaged in developing novel therapeutics targeting melanin production, pigment transfer mechanisms, and photoprotection pathways in individuals with albinism.


North America Pigmentation Disorder Treatment Market, 2020 – 2032 (USD Billion)

In 2023, North America region held a market share of 43.2% in the global hypopigmentation disorder treatment market and is expected to dominate throughout the forecast period.

  • High regional market growth can be attributed to the advanced healthcare infrastructure, high healthcare expenditure, and increase in the skin procedures in the region are contributing to the demand for hypopigmentation disorder treatment.
  • Also, genetic profiling, biomarker identification, and individualized treatment plans enable healthcare providers to tailor therapies to each patient's unique characteristics. Therefore, this personalized approach improves treatment efficacy and patient satisfaction while minimizing adverse effects.

Hypopigmentation Disorder Treatment Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their business portfolios. Also, the companies are actively adopting a multi-pronged approaches to address the rising demand for effective hypopigmentation disorder treatment.

Hypopigmentation Disorder Treatment Market Companies

Prominent players operating in the hypopigmentation disorder treatment industry are as mentioned below:

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • Bayer AG
  • Candela Corporation
  • Galderma
  • Incyte
  • Novartis AG
  • Pfizer Inc.
  • Pierre Fabre group
  • Shiseido Company Limited
  • UNIZA Group

Hypopigmentation Disorder Treatment Industry News

  • In July 2022, Incyte Corporation received the U.S. Food and Drug Administration (FDA) approval Opzelura (ruxolitinib) cream 1.5% for the treatment of non-segmental vitiligo. Opzelura is the first and only FDA-approved product for repigmentation in non-segmental vitiligo, and its approval was based on data from the pivotal Phase 3 TRuE-V clinical trial program. The FDA approval allowed Opzelura to be prescribed for continuous topical use, which helped the company hold a competitive edge in the field of vitiligo treatment.
  • In October 2021, Uniza Group launched a novel solution Vitellus, a combination of Greyverse, Melitane, GL 200, and EUK-134 in the Indian market. Vitellus is a 3-in-1 solution that helps in melamine growth, skin pigmentation, and hair follicle pigmentation, and also acts as a super antioxidant. This helped the company enhance its product offering and strengthen its market position.

The hypopigmentation disorder treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

  • Drugs
    •  By type
      • Corticosteroids
      • Melanocyte-stimulating hormone
      • Other drugs
    • By route of administration
      • Oral
      • Topical
      • Other routes of administration
    • By distribution channel
      • Hospital pharmacies
      • Retail pharmacies
      • Online pharmacies
  • Procedures
    • By type
      • Laser treatment
      • Phototherapy
      • Microdermabrasion
      • Other procedures
    • By end-user
      • Hospitals
      • Dermatology clinics
      • Aesthetic centers
      • Other end-users

Market, By Disease Indication

  • Vitiligo
  • Albinism
  • Other disease indications

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Hypopigmentation disorder treatment market size was USD 3.1 billion in 2023 and is expected to register 6.1% CAGR from 2024-2032 owing to the increasing prevalence of pigmentation disorders such as vitiligo and albinism, along with rising awareness among the population worldwide.

The albinism segment and is expected to register 5.9% CAGR from 2024-2032 due to pharmaceutical companies and research institutions actively engaging in developing novel therapeutics targeting melanin production.

North America hypopigmentation disorder treatment industry held 43.2% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to advanced healthcare infrastructure, high healthcare expenditure, and increase in the skin procedures in the region.

AbbVie Inc., Aclaris Therapeutics, Inc., Bayer AG, Candela Corporation, Galderma, Incyte, Novartis AG, Pfizer Inc., Pierre Fabre group, Shiseido Company Limited, and UNIZA Group, are some of the major hypopigmentation disorder treatment companies worldwide.

Hypopigmentation Disorder Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 266
  • Countries covered: 19
  • Pages: 150
 Download Free Sample